Non-clinical evaluation of HemoClear blood filter in Intrapartum Care

  • Research type

    Research Study

  • Full title

    Use of the HemoClear system for obstetric cell salvage: A pre-clinical proof of concept to cleanse blood salvaged in caesarean sections and vaginal delivery

  • IRAS ID

    294144

  • Contact name

    Dion Osemwengie

  • Contact email

    dion.osemwengie@hemoclear.com

  • Sponsor organisation

    HemoClear B.V.

  • ISRCTN Number

    ISRCTN10504710

  • Duration of Study in the UK

    0 years, 3 months, 1 days

  • Research summary

    Intraoperative cell salvage is the collection of own shed blood to processes and return it to the same person. Cell salvage reduces the infectious and allergenic risks associated with donor blood transfusion, it is recommended in medical guidelines. Maternal mortality is unacceptably high. About 295 000 women died during and following
    pregnancy and childbirth in 2017. As the leading cause for these unnecessary deaths is severe bleeding (mostly bleeding after childbirth), broad use of cell salvage in during deliveries has lifesaving potential.
    Current gold standard cell salvage devices (generally referred to as 'cell savers') are costly, require a trained operator.
    Due to this they are often not available, not affordable or not practical. The novel HemoClear device is an accessible cell salvage filter that allows preparation of shed blood for reinfusion in a simple, cost-effective procedure. Without the need for extensive training, consumables or electricity. This benchtop, non-clinical study aims at investigating the HemoClear device performance in the obstetric field. To this
    end, collected shed blood from 18 women undergoing caesarean section or vaginal delivery will be cleansed. In a paired setup, half of each sample will be processed with the HemoClear device and the other half with a gold standard cell saver. Pre-processed and processed blood quality will be analyzed to determine washing effeciency and compare the novel HemoClear device with the cell saver. No blood components are returned to any patient, no clinical data will be collected.

  • REC name

    HSC REC A

  • REC reference

    21/NI/0015

  • Date of REC Opinion

    9 Feb 2021

  • REC opinion

    Further Information Favourable Opinion